Q1 Earnings Forecast for OmniAb Issued By HC Wainwright

OmniAb, Inc. (NASDAQ:OABI) – Equities research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of OmniAb in a note issued to investors on Thursday, March 5th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.09) per share for the quarter. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.25) EPS, FY2028 earnings at ($0.11) EPS and FY2029 earnings at ($0.06) EPS.

OmniAb (NASDAQ:OABI) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). OmniAb had a negative net margin of 347.04% and a negative return on equity of 23.99%. The firm had revenue of $8.38 million during the quarter, compared to the consensus estimate of $9.00 million.

Other analysts also recently issued reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of OmniAb in a research report on Monday, December 22nd. Benchmark reissued a “buy” rating on shares of OmniAb in a research note on Friday. Finally, Wall Street Zen raised shares of OmniAb from a “sell” rating to a “hold” rating in a report on Saturday. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, OmniAb presently has a consensus rating of “Moderate Buy” and an average target price of $6.67.

OmniAb Stock Performance

Shares of OABI stock opened at $1.99 on Monday. OmniAb has a fifty-two week low of $1.22 and a fifty-two week high of $3.34. The stock’s fifty day moving average price is $1.83 and its two-hundred day moving average price is $1.75. The company has a market cap of $286.48 million, a PE ratio of -3.49 and a beta of 0.13.

Institutional Trading of OmniAb

Hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new position in shares of OmniAb in the first quarter valued at approximately $25,000. Osaic Holdings Inc. increased its position in OmniAb by 214.4% in the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock valued at $25,000 after acquiring an additional 9,716 shares during the period. BNP Paribas Financial Markets increased its position in OmniAb by 92.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock valued at $35,000 after acquiring an additional 10,438 shares during the period. Cerity Partners LLC raised its stake in shares of OmniAb by 111.5% during the second quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock valued at $39,000 after acquiring an additional 11,919 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of OmniAb by 96.6% during the fourth quarter. SG Americas Securities LLC now owns 23,141 shares of the company’s stock worth $43,000 after purchasing an additional 11,369 shares during the period. 72.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Matthew W. Foehr sold 30,843 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $1.71, for a total transaction of $52,741.53. Following the sale, the chief executive officer owned 4,403,277 shares in the company, valued at $7,529,603.67. The trade was a 0.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 84,389 shares of company stock worth $143,959. Insiders own 8.60% of the company’s stock.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.